Advanced search
Publication Cover
Journal of Asthma and Allergy Volume 15, 2022 - Issue
Submit an article Journal homepage
575
Views
23
CrossRef citations to date
0
Altmetric
Original Research

Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study

Andrew N Menzies-Gow1 UK Severe Asthma Network and National Registry, Royal Brompton & Harefield Hospitals, London, UKView further author information
,
Claire McBrien2 Kingston Hospital, London, UKView further author information
,
Bindhu Unni3 Observational and Pragmatic Research Institute, Singapore, SingaporeView further author information
,
Celeste M Porsbjerg4 Respiratory Research Unit, Bispebjerg University Hospital, Copenhagen, DenmarkView further author information
,
Mona Al-Ahmad5 Al-Rashed Allergy Center, Ministry of Health, Microbiology Department, Faculty of Medicine, Kuwait University, Kuwait, KuwaitORCID Iconhttps://orcid.org/0000-0003-2950-5363View further author information
ORCID Icon,
Christopher S Ambrose6 AstraZeneca, Gaithersburg, MD, USAORCID Iconhttps://orcid.org/0000-0003-4175-7336View further author information
ORCID Icon,
Karin Dahl Assing7 Department of Respiratory Medicine, Aalborg University Hospital, Aalborg, DenmarkView further author information
,
Anna von Bülow4 Respiratory Research Unit, Bispebjerg University Hospital, Copenhagen, DenmarkView further author information
,
John Busby8 UK Severe Asthma Network and National Registry, Queen’s University Belfast, Belfast, Northern IrelandView further author information
,
Borja G Cosio9 Son Espases University Hospital-IdISBa-Ciberes, Mallorca, SpainORCID Iconhttps://orcid.org/0000-0002-6388-8209View further author information
ORCID Icon,
J Mark FitzGerald10 The Centre for Lung Health, Vancouver Coastal Health Research Institute, UBC, Vancouver, CanadaView further author information
,
Esther Garcia Gil11 AstraZeneca, Barcelona, SpainView further author information
,
Susanne Hansen12 Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, Copenhagen, DenmarkView further author information
,
Liam G aHeaney8 UK Severe Asthma Network and National Registry, Queen’s University Belfast, Belfast, Northern IrelandView further author information
,
Mark Hew13 Allergy, Asthma & Clinical Immunology Service, Alfred Health, Melbourne, Australia;14 Public Health and Preventive Medicine, Monash University, Melbourne, AustraliaView further author information
,
David J Jackson15 UK Severe Asthma Network andNational Registry, Guy’s and St Thomas’ NHS Trust, London, UK;16 School of Immunology & Microbial Sciences, King’s College London, London, UKView further author information
,
Maria Kallieri17 2nd Respiratory Medicine Department, National and Kapodistrian University of Athens Medical School, Attikon University Hospital, Athens, GreeceView further author information
,
Stelios Loukides17 2nd Respiratory Medicine Department, National and Kapodistrian University of Athens Medical School, Attikon University Hospital, Athens, GreeceORCID Iconhttps://orcid.org/0000-0002-4278-9922View further author information
ORCID Icon,
Njira L Lugogo18 Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USAView further author information
,
Andriana I Papaioannou17 2nd Respiratory Medicine Department, National and Kapodistrian University of Athens Medical School, Attikon University Hospital, Athens, GreeceORCID Iconhttps://orcid.org/0000-0001-9708-3241View further author information
ORCID Icon,
Désirée Larenas-Linnemann19 Directora Centro de Excelencia en Asma y Alergia, Hospital Médica Sur, Ciudad de México, MexicoORCID Iconhttps://orcid.org/0000-0002-5713-5331View further author information
ORCID Icon,
Wendy C Moore20 Pulmonary, Critical Care, Allergy, and Immunologic Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USAView further author information
,
Luis A Perez-de-Llano21 Department of Respiratory Medicine, Hospital Universitario Lucus Augusti, Lugo, SpainORCID Iconhttps://orcid.org/0000-0003-2652-6847View further author information
ORCID Icon,
Linda M Rasmussen22 Allergy Clinic, Department of Dermato-Allergology, Gentofte Hospital, Copenhagen, DenmarkView further author information
,
Johannes M Schmid23 University Hospital of Aarhus, Aarhus, DenmarkView further author information
,
Salman Siddiqui24 University of Leicester, Department of Respiratory Sciences & NIHR Leicester Biomedical Research Centre (Respiratory Theme), Leicester, UKView further author information
,
Marianna Alacqua25 AstraZeneca, Cambridge, UKView further author information
,
Trung N Tran6 AstraZeneca, Gaithersburg, MD, USAView further author information
,
Charlotte Suppli Ulrik26 Department of Respiratory Medicine, Copenhagen University Hospital-Hvidovre, Hvidovre, DenmarkORCID Iconhttps://orcid.org/0000-0001-8689-3695View further author information
ORCID Icon,
John W Upham27 Diamantina Institute & PA-Southside Clinical Unit, The University of Queensland, Brisbane, AustraliaView further author information
,
Eileen Wang28 Division of Allergy & Clinical Immunology, Department of Medicine, National Jewish Health, Denver, CO, USA;29 Division of Allergy & Clinical Immunology, Department of Internal Medicine, University of Colorado School of Medicine, Aurora, CO, USAView further author information
,
Lakmini Bulathsinhala3 Observational and Pragmatic Research Institute, Singapore, Singapore;30 Optimum Patient Care, Cambridge, UKView further author information
,
Victoria A Carter3 Observational and Pragmatic Research Institute, Singapore, Singapore;30 Optimum Patient Care, Cambridge, UKView further author information
,
Isha Chaudhry3 Observational and Pragmatic Research Institute, Singapore, Singapore;30 Optimum Patient Care, Cambridge, UKView further author information
,
Neva Eleangovan3 Observational and Pragmatic Research Institute, Singapore, Singapore;30 Optimum Patient Care, Cambridge, UKView further author information
,
Ruth B Murray3 Observational and Pragmatic Research Institute, Singapore, Singapore;30 Optimum Patient Care, Cambridge, UKView further author information
,
Chris A Price3 Observational and Pragmatic Research Institute, Singapore, Singapore;30 Optimum Patient Care, Cambridge, UKView further author information
&
David B Price3 Observational and Pragmatic Research Institute, Singapore, Singapore;30 Optimum Patient Care, Cambridge, UK;31 Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9728-9992View further author information
ORCID Icon show all
Pages 63-78 | Published online: 13 Jan 2022

References

  • McGregor MC, Krings JG, Nair P, Castro M. Role of biologics in asthma. Am J Respir Crit Care Med. 2019;199:433–445. doi:10.1164/rccm.201810-1944CI
  • Hillas G, Fouka E, Papaioannou AI. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab. Expert Rev Respir Med. 2020;14(4):353–365. doi:10.1080/17476348.2020.1718495
  • Le Floc’h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy Eur J Allergy Clin Immunol. 2020;75(5):1188–1204. doi:10.1111/all.14151
  • Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa1403290
  • Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, Phase 3 trials. Lancet Respir Med. 2015;3(5):355–366. doi:10.1016/S2213-2600(15)00042-9
  • FitzGerald JM, Bleecker ER, Menzies-Gow A, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2018;6:51–64. doi:10.1016/S2213-2600(17)30344-2
  • Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496. doi:10.1056/NEJMoa1804092
  • Ramonell RP, Iftikhar IH. Effect of anti-IL5, anti-IL5R, anti-IL13 therapy on asthma exacerbations: a network meta-analysis. Lung. 2020;198(1):95–103. doi:10.1007/s00408-019-00310-8
  • Menzella F, Ruggiero P, Galeone C, et al. Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma. Pulm Pharmacol Ther. 2020;64:101966. doi:10.1016/j.pupt.2020.101966
  • Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018;52(4):1800703. doi:10.1183/13993003.00703-2018
  • Wang E, Wechsler ME, Tran TN, et al. Characterization of severe asthma worldwide: data from the international severe asthma registry. Chest. 2020;157(4):790–804. doi:10.1016/j.chest.2019.10.053
  • Canonica GW, Alacqua M, Altraja A, et al. International severe asthma registry: mission Statement. Chest. 2020;157(4):805–814. doi:10.1016/j.chest.2019.10.051
  • Fitzgerald JM, Tran TN, Alacqua M, et al. International severe asthma registry (ISAR): protocol for a global registry. BMC Med Res Methodol. 2020;20. doi:10.1186/s12874-020-01065-0
  • Bulathsinhala L, Eleangovan N, Heaney LG, et al. Development of the International Severe Asthma Registry (ISAR): a modified Delphi study. J Allergy Clin Immunol Pract. 2019;7:578–588.e2. doi:10.1016/j.jaip.2018.08.016
  • Ambrose C, Chipps BE, Moore WC, et al. The CHRONICLE study of US adults with subspecialist-treated severe asthma: objectives, design, and initial results. Pragmatic Obs Res. 2020;11:77–90.
  • Moore WC, Panettieri RA, Trevor J, et al. Biologic and maintenance systemic corticosteroid therapy among US subspecialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2020;125(3):294–303.e1. doi:10.1016/j.anai.2020.04.004
  • Global Initiative for Asthma. Global statement for asthma management and prevention 2018. Available from: https://ginasthma.org/wp-content/uploads/2018/04/wms-GINA-2018-report-V1.3-002.pdf. Accessed December 25, 2021.
  • Kuruvilla M, Ariue B, Oppenheimer JJ, Singh U, Bernstein JA. Clinical use of biologics for asthma treatment by allergy specialists: a questionnaire survey. Ann Allergy Asthma Immunol. 2020;125(4):433–439. doi:10.1016/j.anai.2020.06.041
  • Albers FC, Müllerová H, Gunsoy NB, et al. Biologic treatment eligibility for real-world patients with severe asthma: the IDEAL study. J Asthma. 2018;55(2):152–160. doi:10.1080/02770903.2017.1322611
  • Llanos JP, Bell CF, Packnett E, et al. Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study. J Asthma Allergy. 2019;12:43–58. doi:10.2147/JAA.S189676
  • Kim J, Naclerio R. Therapeutic potential of dupilumab in the treatment of chronic rhinosinusitis with nasal polyps: evidence to date. Ther Clin Risk Manag. 2020;16:31–37. doi:10.2147/TCRM.S210648
  • Menzies-Gow A, Bafadhel M, Busse WW, et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020;145(3):757–765. doi:10.1016/j.jaci.2019.12.006

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.